Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2008
11/19/2008EP1268775B1 The high bone mass gene of 11q13.3
11/19/2008EP1210949B1 Lactalbumin for the curative treatment of peptic ulcers
11/19/2008EP1171455B1 Polypeptide-k obtained from momordica charantia and a process for the extraction thereof
11/19/2008EP1112084B1 Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
11/19/2008EP0888120B1 Immunogenic hla binding peptide and its uses to treat hiv infection
11/19/2008EP0802921B1 Human pak65
11/19/2008EP0745122B1 Galanin receptor, nucleic acids, transformed cells and uses thereof
11/19/2008CN101309934A 修饰的伴侣蛋白10 Modified chaperonin 10
11/19/2008CN101309932A Novel mucin glycoprotein and use thereof
11/19/2008CN101309930A Splice variants of erbb ligands, compositions and uses thereof
11/19/2008CN101309700A Therapeutic use of outer shigella protein f (ospf)
11/19/2008CN101309698A Methods for stimulating hair growth by administering bmps
11/19/2008CN101309697A Method of treating patients with a mucinous glycoprotein (muc-1) vaccine
11/19/2008CN101309694A Methods of treating fibrosing diseases by induction of immune tolerance
11/19/2008CN101309678A Medicament for use in connection with cartilage impairment
11/19/2008CN101309674A Pharmaceutical composition
11/19/2008CN101309668A Peroral absorbing medicament preparation and administration method
11/19/2008CN101307346A Method for extracting brain strengthening bioactive peptide from brain tissue of farming animals
11/19/2008CN101307330A BA46 recombinant adeno-associated virus, construction process thereof and applications
11/19/2008CN101307329A Her-2/neu recombinant adeno-associated virus, construction process thereof and applications
11/19/2008CN101307328A CK19 recombinant adeno-associated virus, construction process thereof and applications
11/19/2008CN101307327A CEA recombinant adeno-associated virus, construction process thereof and applications
11/19/2008CN101307326A PSA recombinant adeno-associated virus, construction process thereof and applications
11/19/2008CN101307325A PSMA recombinant adeno-associated virus, construction process thereof and applications
11/19/2008CN101307320A Preparation method and application of recombination human ARC protein with anti - myocardial apoptosis function
11/19/2008CN101307312A Homologous 28-kilodalton immunodominant protein genes of ehrlichia canis and uses thereof
11/19/2008CN101307310A Expression system with recombination protein for increasing yield and immunogenicity
11/19/2008CN101307110A Preparation method of enhancing peptide fragment immunocompetence and use
11/19/2008CN101307105A Human parathyroid hormone 1-34 peptide analogue capable of expressing in series and being released by synchronousacid hydrolysis, preparation method thereof and use
11/19/2008CN101307103A Purification method of follicle stimulating hormone
11/19/2008CN101307102A Human hypoxia inducible factor-1 alpha recombinant adenovirus carrier and uses thereof
11/19/2008CN101307101A Novel modification-specific signal Conus superfamily toxin and uses thereof
11/19/2008CN101307100A Polypeptide fragments of antibiotic peptide, nucleotide sequence thereof and applications
11/19/2008CN101307095A T-cell epitope peptide
11/19/2008CN101307094A Novel nuclear factor ¿Ckappa B p65 subunit antagonizing polypeptide
11/19/2008CN101306197A Administration system of plasminogen activator sustained and controlled release preparation, construction and use thereof
11/19/2008CN101306196A Biodegradable nano-particles bonded with hemoglobin and production method thereof
11/19/2008CN101306195A Recombination human soluble tumor necrosis factor related apoptosis inducing ligand freeze dried protection agents and preparation method thereof
11/19/2008CN101306194A Medicine for treating nerves damage and preparation method thereof
11/19/2008CN101306193A Use of neuritis auxin in preparing wound healing medicine
11/19/2008CN101306192A Use of neuritis auxin in preparing antineoplastic medicine
11/19/2008CN101306191A Use of TLR2 ligand PGN in treating metabolism syndrome
11/19/2008CN100434519C Curing and preventing method
11/19/2008CN100434515C Enzyme combining stabilizer
11/19/2008CN100434439C Genes and polypeptides relating to chronic myeloid leukemia
11/19/2008CN100434437C Biological active peptides comprising isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonine
11/19/2008CN100434117C Suppository for treating chronic cervicitis
11/18/2008US7452987 Interfering RNA molecules
11/18/2008US7452980 Compositions and methods for the diagnosis and treatment of immune disorders
11/18/2008US7452977 Antibody to a kinase capable of site-specific phosphorylation of IκBα
11/18/2008US7452974 Drug targets related to synthase subfamily; alternative splice forms; isolated peptides and antibodies
11/18/2008US7452971 Compositions and methods for modifying toxic effects of proteinaceous compounds
11/18/2008US7452970 G-protein coupled receptors for identifying modulators for prevention and treatment of cardiovascular, urogenital and hypertensive disorders
11/18/2008US7452968 proteins that modulate the growth, differentiation, trafficking and physiology of mammalian cells, e.g., cells of the hematopoietic system and the neuronal system of mammals
11/18/2008US7452967 Caspase recruitment domain (CARD); tumor suppressor genes; oncogenes; antiproliferative agents; antitumor agents; antiinflammatory agents; antiapoptosis
11/18/2008US7452966 GLP-1 analog fusion proteins
11/18/2008US7452965 nine amino acid, disulfide-constrained peptide that selectively bound and was internalized into colon cancer cells; exhibit decreased or a substantially nonexistent immunogenicity in an in vivo system
11/18/2008US7452963 From 7 to 50 amino acids comprising: (1) a lysine residue six to ten residues from a second lysine residue; (2) a histidine residue; and (3) at least 6% lysine residues
11/18/2008US7452916 Administering arginine, lysine; cardiovascular disorder therapy
11/18/2008US7452875 Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
11/18/2008US7452874 Thrombopoietin mimetics
11/18/2008US7452869 For modulating necrosis and treating neurological/ cardiovascular diseases
11/18/2008US7452868 provides release for a period of at least about two months; treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas
11/18/2008US7452867 Use of ADNF polypeptides for treating peripheral neurotoxicity
11/18/2008US7452866 Methods of inhibiting angiogenesis with fragments and homologs of troponin subunit 1
11/18/2008US7452865 Antagonistic analogs of GH RH (2003)
11/18/2008US7452864 chronic ulcers; cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media
11/18/2008US7452863 NGF variants
11/18/2008US7452862 Conformationally-controlled biologically active macrocyclic small molecules as motilin antagonists or ghrelin agonists
11/18/2008US7452861 Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent
11/18/2008US7452860 Zinc-free and low-zinc insulin preparations having improved stability
11/18/2008US7452859 Having serine protease inhibitory activity
11/18/2008US7452858 Administering exendin, or an antagonist thereof; reducing blood glucose concentration
11/18/2008US7452856 partial peptide based upon the amino acid sequences of a guinea-pig-derived antimicrobial polypeptide and partially substituted forms; lipopolysaccharide-cell-binding inhibitor
11/18/2008US7452723 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
11/18/2008US7452717 Carboxylesterase; antitumor agents; drug screening; bioassay
11/18/2008US7452716 Plasmid for use as gene transfer vechicle in the treatment of genetic disorders
11/18/2008US7452715 expression of the lipidated form of the peptidoglycan-associated protein (PAL) of gram-negative bacteria is achieved through the use of a plasmid containing a tightly regulated promoter; bacterial host cell transformed, transduced or transfected with the plasmid
11/18/2008US7452706 Recombinant bacterial phytases and uses thereof
11/18/2008US7452688 Transformed cell with enhanced sensitivity to antifungal compound and use thereof
11/18/2008US7452684 Collagen XXII, a novel human collagen and uses thereof
11/18/2008US7452682 Identification of 5HT2A receptor ligands by selective amplification of cells transfected with receptors
11/18/2008US7452679 Hybridization; phage display; spectroscopy
11/18/2008US7452664 By determining the level of NAD-dependent acetylation and/or ADP ribosylation of a nuclear protein
11/18/2008US7452544 Bacteriocins and novel bacterial strains
11/18/2008US7452543 Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics
11/18/2008US7452538 Death domain containing receptor 4 antibodies and methods
11/18/2008US7452536 Inhibiting OX-2 (also called CD200) gene expression to treat a tumor that is associated with increased CD200 expression; leukemia; phage display screening for antigens; monoclonal antibodies; fusion proteins; use of OX-2 preventing graft rejection, autoimmune disease, and in inducing tumor cell growth
11/18/2008US7452535 Methods of treatment using CTLA-4 antibodies
11/18/2008US7452534 low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life); chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences
11/18/2008US7452533 Antimicrobial polymer conjugate containing lysostaphin and polyethylene glycol
11/18/2008US7452531 Compositions and methods for tumor-targeted delivery of effector molecules
11/18/2008US7452530 Administering a blocking agent of tumor necrosis factors or receptors; treatment of Sin Nombre (SNV), Ebola, Marburg, Lassa, and Dengue viral disease
11/18/2008CA2632032A1 Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
11/18/2008CA2589613A1 Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
11/18/2008CA2434682C Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
11/18/2008CA2406846C Pharmacotherapeutic process and composition for central nervous system disorders
11/18/2008CA2402652C Viscoelastics for use in middle ear surgery
11/18/2008CA2381219C Monomeric protein of the tgf-beta family
11/18/2008CA2373993C Site specific binding system, nuclear imaging compositions and methods
1 ... 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 ... 3163